<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="section" /><meta name="keywords" content="Antiemetics; Vomiting; Antihistamines: nausea and vertigo; Phenothiazines: nausea and vertigo; Prochlorperazine: nausea and vertigo; Perphenazine: nausea; Trifluoperazine: nausea and vertigo; Chlorpromazine: nausea; Droperidol; Haloperidol: nausea and vertigo; Levomepromazine: nausea and vertigo; Metoclopramide: nausea and vomiting; Domperidone: nausea and vomiting; Granisetron; Ondansetron; Palonosetron; 5HT3-receptor antagonists: nausea and vomiting; Dexamethasone: nausea and vertigo; Aprepitant; Fosaprepitant; Nabilone" /><meta name="IX" content="Antiemetics; Vomiting; Antihistamines: nausea and vertigo; Phenothiazines: nausea and vertigo; Prochlorperazine: nausea and vertigo; Perphenazine: nausea; Trifluoperazine: nausea and vertigo; Chlorpromazine: nausea; Droperidol; Haloperidol: nausea and vertigo; Levomepromazine: nausea and vertigo; Metoclopramide: nausea and vomiting; Domperidone: nausea and vomiting; Granisetron; Ondansetron; Palonosetron; 5HT3-receptor antagonists: nausea and vomiting; Dexamethasone: nausea and vertigo; Aprepitant; Fosaprepitant; Nabilone" /><title>4.6 Drugs used in nausea and vertigo: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="3398.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="3398.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=3398.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2055.htm">4 Central nervous system</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="3387.htm" title="Previous: 4.5.2 Centrally acting appetite suppressants">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="8535.htm" title="Next: Vomiting during pregnancy">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_3398">4.6 Drugs used in nausea and vertigo</h1><?highlighter on?><div id="pC" class="jN"><div><p>Antiemetics should be prescribed only when the cause of vomiting is known because otherwise
they may delay diagnosis, particularly in children. Antiemetics are
unnecessary and sometimes harmful when the cause can be treated, such
as in diabetic ketoacidosis, or in <span>digoxin</span> or antiepileptic
overdose.</p><p>If antiemetic drug treatment is indicated, the drug is chosen
according to the aetiology of vomiting.</p><p><b>Antihistamines</b> are effective against nausea and
vomiting resulting from many underlying conditions. There is no evidence
that any one antihistamine is superior to another but their duration
of action and incidence of adverse effects (drowsiness and antimuscarinic
effects) differ.</p><p>The <b>phenothiazines</b> are dopamine antagonists and act
centrally by blocking the chemoreceptor trigger zone. They are of
considerable value for the prophylaxis and treatment of nausea and
vomiting associated with diffuse neoplastic disease, radiation sickness,
and the emesis caused by drugs such as opioids, general anaesthetics,
and cytotoxics. <b><span>Prochlorperazine</span></b>, <b><span>perphenazine</span></b>, and <b><span>trifluoperazine</span></b> are less sedating than <b>chlorpromazine</b>; severe dystonic reactions sometimes occur with phenothiazines,
especially in children. Some phenothiazines are available as rectal
suppositories, which can be useful in patients with persistent vomiting
or with severe nausea; <span>prochlorperazine</span> can also
be administered as a buccal tablet which is placed between the upper
lip and the gum.</p><p><b>Droperidol</b> is a butyrophenone, structurally related to haloperidol, which blocks
dopamine receptors in the chemoreceptor trigger zone. </p><p>Other antipsychotic drugs including <b>haloperidol</b> and <b>levomepromazine</b> are used for the relief of nausea and vomiting
in terminal illness (see <a title="target-block: misc conditions nausea and vom" href="29458.htm#_120532">Palliative Care</a>).</p><div id="_3398.1"><p><b>Metoclopramide</b> is an effective antiemetic and its activity
closely resembles that of the phenothiazines. Metoclopramide also
acts directly on the gastro-intestinal tract and it may be superior
to the phenothiazines for emesis associated with gastroduodenal, hepatic,
and biliary disease. In postoperative nausea and vomiting, metoclopramide
in a dose of 10 mg has limited efficacy. High-dose metoclopramide
injection is now less commonly used for cytotoxic-induced nausea and
vomiting. As with the phenothiazines, metoclopramide can induce acute
dystonic reactions involving facial and skeletal muscle spasms and
oculogyric crises. These dystonic effects are more common in the young
(especially girls and young women) and the very old; they usually
occur shortly after starting treatment with metoclopramide and subside
within 24 hours of stopping it. Injection of an antiparkinsonian drug
such as procyclidine (<a title="sub-section: Antimuscarinic drugs used in parkinsonism" href="3654.htm#_3654">section 4.9.2</a>) will
abort dystonic attacks.</p></div><p><b><span>Domperidone</span></b> acts at the chemoreceptor trigger zone; it is used for the relief
of nausea and vomiting, especially when associated with cytotoxic
therapy. It has the advantage over metoclopramide and the phenothiazines
of being less likely to cause central effects such as sedation and
dystonic reactions because it does not readily cross the blood-brain
barrier. In Parkinson’s disease, it is used to prevent nausea and
vomiting during treatment with <span>apomorphine</span> and
also to treat nausea caused by other dopaminergic drugs (<a title="sub-section: Dopaminergic drugs used in parkinsonism" href="3632.htm#_3632">section 4.9.1</a>). <span>Domperidone</span> is also used to treat vomiting due to emergency
hormonal contraception (<a title="monograph-family: Hormonal methods" href="130057.htm#_130057">section 7.3.5</a>). </p><p><b><span>Granisetron</span></b>, <b><span>ondansetron</span></b>, and <b><span>palonosetron</span></b> are specific 5HT<sub>3</sub>-receptor antagonists which block 5HT<sub>3</sub> receptors
in the gastro-intestinal tract and in the CNS. Granisetron and ondansetron
are of value in the management of nausea and vomiting in patients
receiving cytotoxics and in postoperative nausea and vomiting. Palonosetron
is licensed for prevention of nausea and vomiting associated with
moderately or highly emetogenic cytotoxic chemotherapy.</p><p><b>Dexamethasone</b> (<a title="monograph: DEXAMETHASONE" href="4271.htm#_4271">section 6.3.2</a>) has antiemetic effects and it is used in vomiting
associated with cancer chemotherapy. It can be used alone or with
metoclopramide, <span>prochlorperazine</span>, <span>lorazepam</span>, or a 5HT<sub>3</sub>-receptor antagonist (<a title="target-block: Cytotoxic-induced nausea and vomiting" href="100100.htm#_100100.1">section 8.1</a>).</p><p><b>Aprepitant</b> and <b>fosaprepitant</b> are neurokinin 1-receptor antagonists licensed for the prevention
of acute and delayed nausea and vomiting associated with cisplatin-based
cytotoxic chemotherapy; they are given with dexamethasone and a 5HT<sub>3</sub>-receptor antagonist.</p><p><b><span>Nabilone</span></b> is a synthetic cannabinoid with antiemetic
properties. It may be used for nausea and vomiting caused by cytotoxic
chemotherapy that is unresponsive to conventional antiemetics. Side-effects
such as drowsiness and dizziness occur frequently with standard doses.</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="8535.htm" title="Vomiting during pregnancy">Vomiting during pregnancy</a></li><li><a href="106071.htm" title="Postoperative nausea and vomiting">Postoperative nausea and vomiting</a></li><li><a href="106072.htm" title="Motion sickness">Motion sickness</a></li><li><a href="106073.htm" title="Other vestibular disorders">Other vestibular disorders</a></li><li><a href="106074.htm" title="Cytotoxic chemotherapy">Cytotoxic chemotherapy</a></li><li><a href="106075.htm" title="Palliative care">Palliative care</a></li><li><a href="106076.htm" title="Migraine">Migraine</a></li><li id="_3399"><a href="3399.htm" title="Antihistamines">Antihistamines</a></li><li id="_3412"><a href="3412.htm" title="Phenothiazines and related drugs">Phenothiazines and related drugs</a></li><li id="_3428"><a href="3428.htm" title="Domperidone and metoclopramide">Domperidone and metoclopramide</a></li><li id="_3440"><a href="3440.htm" title="5HT3-receptor antagonists">5HT<sub>3</sub>-receptor antagonists</a></li><li id="_128407"><a href="128407.htm" title="Neurokinin-receptor antagonists">Neurokinin-receptor antagonists</a></li><li id="_3447"><a href="3447.htm" title="Cannabinoid">Cannabinoid</a></li><li id="_3450"><a href="3450.htm" title="Hyoscine">Hyoscine</a></li><li id="_3453"><a href="3453.htm" title="Other drugs for Ménière’s disease">Other drugs for Ménière’s disease</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="3387.htm">Previous: 4.5.2 Centrally acting appetite suppressants</a> | <a class="top" href="3398.htm#">Top</a> | <a accesskey="]" href="8535.htm">Next: Vomiting during pregnancy</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>